Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?

Jack R AndrewsMohamed E AhmedR Jeffrey KarnesEugene KwonAlan H Bryce

Published in: The Prostate (2020)

Our data indicates that sequence of systemic therapy may influence outcomes for mCRPC and that docetaxel should be considered before 2nd generation ADT. Our results support the importance of earlier chemotherapy in the castration resistant state.

Keyphrases

prostate cancer
locally advanced
squamous cell carcinoma
radical prostatectomy
small cell lung cancer
electronic health record
big data
type diabetes
machine learning
metabolic syndrome
rectal cancer
adipose tissue
replacement therapy
drug induced
bone marrow
artificial intelligence
smoking cessation